Plain-English translation of NCT04663750 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two treatments for a serious eye condition called submacular hemorrhage, which causes bleeding behind the retina in people with wet age-related macular degeneration. Some patients will receive aflibercept (an eye injection) alone, while others will receive eye surgery combined with aflibercept injections. The trial aims to find out which approach helps preserve vision better.
Submacular hemorrhage is a rare but devastating complication that can cause severe vision loss or blindness if untreated. There is currently no proven best way to treat it, so doctors use different approaches with varying results. This trial will help establish which treatment works best to protect patients' sight.
You likely qualify if…
You likely don't qualify if…
After screening and confirming your diagnosis, you will be randomly assigned to one of two groups. If assigned to surgery, you will have an eye procedure plus receive injections of the medication. If assigned to injections alone, you will receive the medication by injection into your eye at baseline, month 1, month 2, and then regularly thereafter. Both groups will have multiple follow-up visits to check your vision and eye health throughout the trial.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany